



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an Independent Licensee of the Blue Cross and Blue Shield Association

## Medical Policy

# Percutaneous Electrical Nerve Field Stimulation for Functional Abdominal Pain Disorders

### Table of Contents

- [Policy: Commercial](#)
- [Coding Information](#)
- [Information Pertaining to All Policies](#)
- [Policy: Medicare](#)
- [Description](#)
- [References](#)
- [Authorization Information](#)
- [Policy History](#)
- [Endnotes](#)

### Policy Number: 922

BCBSA Reference Number: 2.01.106 (For Plan internal use only)

NCD/LCD: N/A

### Related Policies

Cranial Electrotherapy Stimulation and Auricular Electrostimulation [#362](#)

### Policy<sup>1</sup>

## Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO Blue<sup>SM</sup> and Medicare PPO Blue<sup>SM</sup> Members

IB-STIM® may be considered **MEDICALLY NECESSARY** in children and adolescents when **ALL** of the following criteria is met:

- 11-21 years of age **AND**
- Patient must be diagnosed with a ROME IV defined-functional gastrointestinal disorder (These include functional abdominal pain, functional abdominal pain syndrome, irritable bowel syndrome, functional dyspepsia, and abdominal migraine) **AND**
- Organic GI disease must have been ruled out **AND**
- The problem has been present for at least 9 months **AND**
- The patient has tried and failed medications in all 3 categories: acid suppression (H2-blockers or PPIs), antispasmodics or motility medications (hyoscyamine, dicyclomine, erythromycin/linaclotide, prucalopride) and neuromodulators (amitriptyline/nortriptyline/gabapentin/periactin/aprepitant), in addition to diet modification.

All other uses of IB-STIM® device is considered **INVESTIGATIONAL**.

### Prior Authorization Information

#### Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

#### Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	<b>Outpatient</b>
<b>Commercial Managed Care (HMO and POS)</b>	Prior authorization is <b>not required</b> .
<b>Commercial PPO and Indemnity</b>	Prior authorization is <b>not required</b> .
<b>Medicare HMO Blue<sup>SM</sup></b>	Prior authorization is <b>not required</b> .
<b>Medicare PPO Blue<sup>SM</sup></b>	Prior authorization is <b>not required</b> .

## CPT Codes / HCPCS Codes / ICD Codes

*Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.*

*Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.*

*The following codes are included below for informational purposes only; this is not an all-inclusive list*

### CPT Codes

The above **medical necessity criteria MUST be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:**

### CPT Codes

<b>CPT codes:</b>	<b>Code Description</b>
0720T	Percutaneous electrical nerve field stimulation, cranial nerves, without implantation

### Description

IB-STIM is a percutaneous electrical nerve field stimulator (PENFS) system is intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS). The IB-STIM is intended to be used for 120 hours per week up to 4<sup>1</sup> consecutive weeks, through application to branches of Cranial Nerves V, VII, IX and X, and the occipital nerves identified by transillumination, as an aid in the reduction of pain when combined with other therapies for IBS. The IB-STIM procedure is typically performed in an office setting.

This nonsurgical device works by sending electrical impulses into the cranial nerve bundles located in the ear. The stimulation targets the brain areas that are involved with processing pain, and aids in the reduction of functional abdominal pain, that is associated with inflammatory bowel syndrome (IBS).

### Summary

Percutaneous Electrical Nerve Field Stimulation (PENFS) is a noninvasive treatment option for pediatric patients with functional bowel disorders including irritable bowel syndrome. This noninvasive device delivers percutaneous electrical nerve field stimulation to the external ear and is a safe and effective therapy for pediatric abdominal pain-related functional gastrointestinal disorders in pediatric patients with functional abdominal pain disorders. Studies showed that PENFS modulates central pain pathways and attenuates visceral hyperalgesia.

The current standard for children with functional abdominal pain is to use off-label medications, most of which have serious side-effects and black-box warnings. These medications include tricyclic antidepressants (amitriptyline), selective serotonin reuptake inhibitor (SSRIs), prokinetics, gabapentin and cycloproheptadine.

The evidence includes 2 randomized, double-blind, sham-controlled trial. Auricular neurostimulation reduces abdominal pain scores. PENFS has proven to be an effective and safe treatment for pediatric patients with abdominal pain disorders. Studies concluded that PENFS improves overall wellbeing in adolescents with abdominal pain. PENFS with Neuro-stim (IB-STIM) showed an 81% improvement in overall symptoms, and approximately 59% of test subjects showed at least a 30% reduction in their worst pain. *Kovacic (2017); Krasaelap (2020)*

Clinical input obtained in 2021 was in agreement that PENFS is medically necessary for the management of functional gastrointestinal disorders. There are no other IBS approaches that attain the level of clinical efficacy of IB-STIM. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

## Policy History

Date	Action
7/2023	Annual policy review. Policy statements unchanged.
7/2022	Clarified coding information
3/2022	New medical policy describing medically necessary indications. Effective 3/1/2022.

## Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

## References

1. Gupta, S., Schaffer, G., & Saps, M. Pediatric irritable bowel syndrome and other functional abdominal pain disorders; an update of non-pharmacological treatments. *Expert Review of Gastroenterology & Hepatology*. 2018; 12(5): 447-456.
2. Kovacic, K, Hainsworth, M., et al. [Neurostimulation for abdominal pain-related functional gastrointestinal disorders in adolescents: a randomised, double-blind, sham-controlled trial](#). *The Lancet: Gastroenterology & Hepatology*. 2017; 2(10): 727-737.
3. Madani, S., Parikh, S., et al. Long-term study of children with ROME III functional gastrointestinal disorders managed symptomatically in a biophysical model. *Gastroenterol Res*. 2017;10(2): 84-91.
4. Walker, L.S., Dengler-Crish, C.M., et al. Functional abdominal pain in childhood and adolescence increases risk for chronic pain in adulthood. *Pain*. 2010; 150(3); 568-572
5. Non-implanted nerve stimulator for functional abdominal pain relief. Regulatory Class: Class II Device. [https://www.accessdata.fda.gov/cdrh\\_docs/pdf18/DEN180057.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf18/DEN180057.pdf)
6. Amornluck Krasaelap, Manu R Sood, B U K Li et al. [Efficacy of Auricular Neurostimulation in Adolescents with Irritable Bowel Syndrome in a Randomized, Double-Blind Trial](#). *Clin Gastroenterol Hepatol*. 2020 Aug;18(9):1987-1994.e2.
7. Katja Kovacic, Jacek Kolacz, Gregory F. Lewis et al. [Impaired Vagal Efficiency Predicts Auricular Neurostimulation Response in Adolescent Functional Abdominal Pain Disorders](#). *Am J Gastroenterol* 2020 Sep;115(9):1534-1538.
8. de Bruijn CMA, et al. [Antidepressants for functional abdominal pain disorders in children and adolescents](#). *Cochrane Database Syst Rev*. 2021.
9. Gottfried-Blackmore A et al. [Noninvasive vagal nerve stimulation for gastroenterology pain disorders](#). *Pain Manag*. 2021 Jan;11(1):89-96.

## Endnotes

---

<sup>1</sup> Based on expert opinion.

---

**Regulatory Status:** The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has approved IB-Stim, a prescription device for the following indications:

The IB-Stim is a percutaneous electrical nerve field stimulator (PENFS) system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS). The IB-Stim is intended to be used for 120 hours per week up to 3 consecutive weeks, through application to branches of Cranial Nerves V, VII, IX and X, and the occipital nerves identified by transillumination, as an aid in the reduction of pain when combined with other therapies for IBS.

**Regulatory Class:** FDA classified the IB-Stim as Class II device. This device does not meet the Centers for Medicare and Medicaid Services definition of Durable Medical Equipment.  
[https://www.accessdata.fda.gov/cdrh\\_docs/pdf18/DEN180057.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf18/DEN180057.pdf)